# Additional file 2:

Figure S1 Risk of bias assessment (a) Risk of bias graph; (b) Risk of bias summary.

Figure S2 Rankograms for six outcomes (a) MMR within 12 months; (b) CCyR within 12 months; (c) Progression to AP-CML; (d) Serious AEs; (e) Overall discontinuation; (f) Discontinuation for drug-related AEs.

Figure S3 Funnel plots for six outcomes (a) MMR within 12 months; (b) CCyR within 12 months; (c) Progression to AP-CML; (d) Serious AEs; (e) Overall discontinuation; (f) Discontinuation for drug-related AEs.

Figure S1 Risk of bias assessment

### (a) Risk of bias graph

(b) Risk of bias summary

Figure S2 Rankograms for six outcomes

"A" to "O" refer to each treatment. A: Imatinib 400mg QD; B: Imatinib 600mg QD; C: Imatinib 800mg QD; D: IFN-α + Ara-C; E: Imatinib 400mg QD + Ara-C; F: Imatinib 400mg QD + IFN-α; G: Nilotinib 300mg BID; H: Nilotinib 400mg BID; I: Dasatinib 100mg QD; J: Radotinib 300mg BID; K: Radotinib 400mg BID; L: Bosutinib 400mg QD; M: Bosutinib 500mg QD; N: Ponatinib 45mg QD; O: Imatinib 400mg QD after IFN-α.

(a) MMR within 12 months

(b) CCyR within 12 months

(c) Progression to AP-CML

Rank Probability

Legend: Rank 1, Rank 2, Rank 3, Rank 4, Rank 5, Rank 6, Rank 7, Rank 8, Rank 9, Rank 10, Rank 11, Rank 12

(d) Serious AEs

Rank Probability

Legend: Rank 1, Rank 2, Rank 3, Rank 4, Rank 5, Rank 6, Rank 7, Rank 8, Rank 9, Rank 10, Rank 11

(e) Overall discontinuation

Rank Probability



(f) Discontinuation for drug-related AEs

Rank Probability

Figure S3 Funnel plots for six outcomes

a

MMR within 12 months

b

CCyR within 12 months

c

Progression to AP−CML

d

Serious AEs

e

Overall discontinuation

f

Discontinuation for drug−related AEs